Introduction
============

Generic and condition specific health related quality of life (HRQL) questionnaires, such as the SF-36 and EORTC QLQ-C30 or FACT respectively, that assess physical and psychosocial functioning are commonly used in oncological practice and research \[[@B1]-[@B3]\]. The cancer specific scales have additional measures to detect the adverse effects of chemo- or radiotherapy \[[@B2],[@B3]\].

Interviews with cancer patients have found a broader range of factors influencing quality of life than is captured in current HRQL measures \[[@B4]-[@B6]\]. Cancer-related Fatigue Syndrome (CRF) is one of the most significant factors determining HRQL in cancer patients. 58% of all outpatients \[[@B7]\] cite it as one of the most burdensome symptoms and it affects up to 92% of all patients undergoing chemotherapy \[[@B8]\]. 34% of breast cancer patients report fatigue 5 to 10 years after diagnosis \[[@B9]\]. Research on correlates of CRF open up new therapeutic approaches and opportunities for intervention \[[@B10],[@B11]\]. For example, there is increasing research interest in sleep disturbances. A cross-sectional study of 982 cancer patients found sleep disorders in 31% of patients \[[@B12]\] and in disease-free breast cancer patients 46% reported these symptoms between one to three years after initial diagnosis \[[@B13]\]. During chemotherapy 59.5% out of 991 patients reported sleep disturbances, of which 28.5% meet the diagnostic criteria for an insomnia syndrome (in breast cancer patients: 69.6% and 36% respectively) \[[@B14]\]. In the case of patients with stage IV colorectal carcinoma actigraphic measurements show a disturbed rest- and reduced daily activity rhythm coincides not only with reduced HRQL but also with reduced survival time \[[@B15]\].

In oncological research to date there has been little investigation of autonomic regulation and functional disorders which are associated with sleep problems and general feelings of ill health \[[@B16]\], although in rehabilitation medicine the new international classification of functioning (ICF) clearly articulates autonomic and physical functions as important outcomes \[[@B17],[@B18]\]. Our concept of autonomic regulation (aR) encompasses individual autonomic functions and the rest-activity rhythm. Rudolf Steiner, the founder of anthro-posophic medicine, highlighted in the 1920s the potential role of autonomic regulation in sustaining health and the development of illness \[[@B19]\]. After initial studies which did not result in sufficient reliability \[[@B20],[@B21]\] we developed a trait-marker questionnaire on autonomic regulation (initially referred to as endogenous regulation): trait-aR. Autonomic regulation (aR) refers to the state of regulation of different autonomic functions in the rhythmic cycle of rest and activity over the course of the day. aR is effected by constitution, gender, age and illness. Under physiological conditions it is a stable trait, but in the context of illness or psychological disturbance a loss of regulation can occur which leads to a decreased aR \[[@B22]\]. We have validated a short version of Trait-aR with 12 items capturing the rest-activity- and orthostatic-circulatory regulation \[[@B23]\] and a longer version with 18 items which includes digestive regulation, too \[[@B22]\].

Loss of aR occurs in patients with a range of medical conditions, including some cancers \[[@B24],[@B25]\]. Cohen & Mount focus on the important issue of \"good\" days and \"bad\" days for patients with cancer and our relative ignorance about what drives this variation \[[@B26]\]. With regards to aR this means that the frequently changing condition of patients with metastatic cancer or of those receiving oncological treatment is possibly not being sufficiently measured with the Trait-aR scale, which captures autonomic constitution together with current regulation. The aim of the two linked studies we report in this paper was to develop and validate a questionnaire on autonomic regulation referring to the previous week (State-aR) which captures the current state of regulation more precisely and to distinguish between constitutional autonomic regulation and loss of regulation due to illness or side effects of treatment.

Methods
=======

Sample population
-----------------

In the first study we tested tool reliability, conducted a factor analysis and analysed concurrent validity. In the second study we measured responsiveness to change in the context of chemotherapy treatment.

Study 1: Item detection, reliability and validity
-------------------------------------------------

An expert panel using an informal consensus method identified 23 items from the trait version questionnaire on autonomic regulation that were judged relevant to the current (past week) autonomic state (see assessment instruments).

We carried out the first study in the departments of General Internal Medicine and Gastroenterology at the Gemeinschaftskrankenhaus Havelhöhe (Berlin), as well as in the hospital\'s specialist oncology practice between January 2003 and February 2004.

Consecutively recruited patients with histologically confirmed malignant tumours were matched by age (± 5 years) and gender with participants from a healthy control group, recruited opportunistically from hospital staff and their families, who had no known acute or chronic condition. Table [1](#T1){ref-type="table"} shows the demographic profile Table [2](#T2){ref-type="table"} the clinical and treatment characteristics of the participants and Table [3](#T3){ref-type="table"} the range of malignancies in participating patients. At the time of questionnaire administration, at least two weeks had elapsed since a participant\'s last operation, chemotherapy or radiotherapy session. Exclusion criteria included patients with a Karnofsky Index (KPI) \< 50%, patients with a manifest psychosis or badly controlled pain and participants aged \< 18 years or \> 85 years.

###### 

Sociodemographic data of patients and healthy controls of study 1 and 2.

                                     a\) Study 1                                       b\) Study 2     
  -------------------- ------------- ---------------------------- -------------------- --------------- ----------------
                                     [**Cancer Patients**]{.ul}   [**Control**]{.ul}   [**BC**]{.ul}   [**CRC**]{.ul}
                                                                                                       
  **Age (y)**          mean ± SD     58.8 ± 11.6                  59.9 ± 10.3          54.3 ± 11.6     62.4 ± 10.6
                       min/max       30/83                        32/81                37/71           33/76
                                                                                                       
  **Gender**           Women         41                           41                   17              13
                       Men           16                           16                   0               12
                                                                                                       
  **Marital status**   Married       41                           20                   4               17
                       stable        2                            4                    4               3
                       partnership                                                                     
                       Single        2                            6                    2               1
                       Divorced      7                            11                   4               1
                       Widowed       5                            6                    1               3
                       Missing       0                            10                   2               0

###### 

Overview of tumour stage, diagnosis duration, Karnofsky performance index, haemoglobin and therapy.

  Study 1: Cancer group                                Study 2:                        BC                            CRC          
  ---------------------------------------------------- ------------------------------- ----------------------------- ------------ ------------
  **Metastasis or generalised stage**                                                                                             
   Yes                                                 35 (61.4%)                                                    2            3
   No                                                  24 (38.6%)                      Stage 1:                      3            0
                                                                                       Stage 2:                      8            2
                                                                                       Stage 3:                      4            18
                                                                                       Missing:                      0            2
                                                                                                                                  
  **Initial diagnosis (years)**                        **Initial diagnosis (month)**                                              
   Mean(SD)                                            2.9 (3.1)                                                     1.3 (1.0)    1.4 (0.5)
   Median                                              2.0                                                           1.0          1.0
   Min/Max                                             0/12                                                          1/5          1/2
                                                                                                                                  
  **Karnofsky-lndex (%)**                                                                                                         
   Mean (SD)                                           81.8(11.6)                                                    86.7(10.5)   88.7 (9.2)
   Median                                              90                                                            90           90
                                                                                                                                  
  **Haemoglobin (gr/dl)**                                                                                                         
   Mean (SD)                                           12.1 (1.84)                                                   13.0(1.28)   13.7(6.8)
   Median                                              12.5                                                          13.2         12.65
   Anemia (\< 12)                                      22 (38.5%)                                                    2(11.1%)     9 (36.0%)
                                                                                                                                  
  **Therapies received at the point of questioning**                                   **after first questioning**                
                                                                                                                                  
   **Operation because of cancer**                                                                                                
   Yes                                                 39 (68.4%)                                                    14(82.3%)    25(100%)
                                                                                                                                  
   **Chemotherapy**                                                                                                               
   Yes                                                 31 (54.4%)                                                    17 (100%)    25 (100%)
                                                                                                                                  
                                                                                       **Chemotherapy Scheme**                    
                                                                                       CMF + RAD                     2            
                                                                                       EC or EC +                    7            
                                                                                       RAD                                        
                                                                                       EC/CMF or                     3            
                                                                                       EC/CMF +                                   
                                                                                       RAD                                        
                                                                                       FEC or FEC +                  1            
                                                                                       RAD                                        
                                                                                       EC/Tac                        1            
                                                                                       Tac/other                     2            
                                                                                       5FU (Mayo                                  5
                                                                                       mod/Ardatan)                               
                                                                                       5FU + RAD                                  5
                                                                                       FOLFOX                                     12
                                                                                       FOLFOX +                                   1
                                                                                       RAD                                        
                                                                                       OXALI mono or others                       2
                                                                                                                                  
   **Radiotherapy**                                                                                                               
   Yes                                                 14 (24.6%)                                                    6 (35.2%)    0(0)
                                                                                                                                  
   **Antihormonal therapy**                                                                                                       
   Yes                                                 13 (22.8%)                                                    6 (35.2%)    0(0)
                                                                                                                                  
   **Mistletoe therapy**                                                                                                          
   Yes                                                 57 (100%)                                                     17 (100%)    25 (100%)

###### 

Tumour diagnoses of patients with malignant tumours.

  Included                                Frequency   Percents
  --------------------------------------- ----------- ----------
  B-chronic lymphatic leukaemia (B-CLL)   1           1.8
  B-cell Lymphoma (NHL)                   2           3.5
  Breast cancer                           16          28.1
  Bronchial carcinoma (NSCLC)             5           8.8
  Carcinoma unclear primary (CUP)         1           1.8
  Cervix carcinoma                        1           1.8
  Colon carcinoma                         4           7.0
  Gallbladder carcinoma                   1           1.8
  Hypernephroma                           1           1.8
  Leiomyosarcoma                          1           1.8
  Melanoma                                1           1.8
  Ovarian carcinoma                       2           3,5
  Ovarian sarcoma                         1           1.8
  Pancreatic cancer                       2           3.5
  Pharynx cancer                          1           1.8
  Plasmocytoma                            4           7.0
  Pleuramesothelioma                      3           5.3
  Prostate cancer                         3           5.3
  Rectal carcinoma                        2           3.5
  Thymus gland carcinoma                  1           1.8
  Thyroid carcinoma                       2           3.5
  Tonsillar carcinoma                     1           1.8
  Urethral cancer                         1           1.8
  Total                                   57          100.0

After the study was explained and consent was obtained, the State-aR questionnaire was administered. The target for the test-retest analysis was at least 50% of all participants. The questionnaire was re-administered to participants 1) who were reviewed as in- or outpatients in our centres or 2) who consented to retest when they initially completed the questionnaire and were mailed the second questionnaire after a median of four weeks. All participants asked to complete the second questionnaire consented to do so.

Assessment instruments
----------------------

A group of experts (oncologist, internist, gastroenterologist, sleep specialist, general practitioner and statistician) compiled 23 items largely derived from the Trait-aR scale with a clear focus on the clinically relevant last week, with topics of rest/activity, circadian well-being, motor skills, orthostatic and circulatory, digestive, thermo- and sweat regulation. The scale structure of the trait scale was retained as much as possible and items were re-worded in terms of the past week; \'travel sickness\', \'dizziness from circular motions (e.g. when on a round-about)\' could not be used in that context and were therefore replaced. The item \'cold and cold sweaty extremities\' was split into \'cold extremities\' and \'cold and sweaty extremities\'. The following new items were included: \'fine motor skills\', \'activity-dependent sweating\', \'stool consistency\' and \'vivid dreams\' (Table [4](#T4){ref-type="table"}). Each question has five possible answers which are rated with a five-point Likert scale from 1 to 5 (\'not at all\' to \'very\'), or in the case of negative questioning, rated inversely (Table [4](#T4){ref-type="table"}). The question relating to frequency of bowel movements offers different possible answers for the frequency of different stool consistencies.

###### 

The list of items of the State version on autonomic regulation (State aR) with the four subscales and the different answer possibilities and their scoring values.

  Validated questions on State-aR                                    Possible answers
  ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------
  I had cold hands or feet                                           not at all (5), rarely (4), sometimes (3), quite a lot (2), a lot (1)
  I was able to fall asleep                                          very well (5)~T~fairly well (4), sometimes (3), hardly ever (2), not at all (1)
  I had to pull myself together to do things.                        not at all (5), hardly (4), sometimes (3), quite a lot (2), a lot (1)
  I felt rested in the morning                                       very much so (5), fairly so (4), sometimes (3), hardly (2), not at all (1)
  I suffered from stomach rumbling                                   not at all (5), rarely (4), sometimes (3), quite a lot (2), a lot (1)
  There were situations where 1 felt                                 a lot (1), quite a lot (2), sometimes (3), rarely (4), not at all (5)
  less competent or skilful than usual                               
  My sleep was restless                                              not at all (5), rarely (4), sometimes (3), quite a lot (2), a lot (1)
  I had cold and sweaty hands or feet                                not at all (5), rarely (4), sometimes (3), quite a lot (2), a lot (1)
                                                                     
  I felt dizzy when turning around                                   not at all (5), rarely (4), sometimes (3), quite a lot (2), a lot (1)
  I felt dizzy when I got up in the morning                          not at all (5), rarely (4), sometimes (3\'. quite a lot (2), a lot (1)
  I felt dizzy when turning around quickly                           not at all (5), rarely (4), not sure (3), quite a lot (2), a lot (1)
  I felt dizzy when getting up or bending down                       not at all (5), rarely (4), sometimes (3), quite a lot (2), a lot (1)
                                                                     
  I suffered from night sweats                                       a lot (1), quite a lot (2), sometimes (3), rarely (4), not at all (5)
  I sweated                                                          a lot (1), quite a lot (2), sometimes (3), rarely (4) not at all (5)
  I sweated even during light physical activity                      a lot (1), quite a lot (2), sometimes (3), rarely (4), not at all (5)
                                                                     
  I had bowel movements                                              3 times/day (5), 2 times/day (4), 1/day (3), 3-4 times/week (2), 1-2 times/week
  I had bowel movements - as always at the same time(s) of the day   not at all (1), to a small extend (2), don\'t know (3), to a large extend (4), fully (5)
  I suffered from constipation                                       not at all (5), rarely (4), sometimes (3). quite a lot (2), a lot (1)
                                                                     
  I felt best                                                        in the morning (5), best in the morning (4), at lunchtime (3), best in the evening (2), in the evening (1)
  I remembered dreaming                                              not at all (5), rarely (4), not sure (3), quite a lot (2), a lot (1)
  My dreams were vivid                                               very vivid (0), quite vivid (1), moderately so (2), hardly (3), not at all (4), I cannot remember my dreams (5)
  I was able to digest big meals                                     very well (5), quite well (4), sometimes (3), not very well (2), not at all (1), I did not eat any big meals (0)
  The stool consistency was:                                         liquid (5), pasty (4), formed (3), very formed (2), hard (1)

The items are arranged from top to bottom for State rest/activity, State orthostatic-circulatory, State digestive and State thermo-sweating regulation. List of the non-validated items with answers and scoring values.

Next to the 23 state-aR items (Table [4](#T4){ref-type="table"}) the following questionnaires were included in the validation study as congruence (1) and convergent criteria (2-6):

1\) The Trait-aR questionnaire measuring the usual autonomic functioning of an individual with an 18-item scale in three subscales (orthostatic-circulatory, rest/activity regulation and digestive). Trait-aR measures with a three-point Likert scale (18-54) with a satisfactory - good reliability and good validity. Higher scores indicate better aR. We used this scale to measure congruence and to validate the state/trait concept and to test a hypothesised difference in responsiveness \[[@B22]\].

2\) A 16 item questionnaire measuring \'self-regulation\' (SRS) developed by Grossarth-Maticek \[[@B27]\]. The questionnaire measures self-regulation and health-building activity in two subscales with a six-point Likert scale. The 16 items are added and divided by 16 to obtain a total score (1-6). Subscale 1 is termed \"Ability to Change Behaviour in order to Reach Goals\", and subscale 2 \"Achieve Satisfaction and Well-Being\", which therefore has a hedonistic connotation. Higher scores indicate better self-regulation. the validity and reliability of the sum- and subscales are good to very good \[[@B27],[@B28]\].

3\) The German version of the \'Hospital Anxiety and Depression Scale\' (HADS-D) consisting of 14 items (7 for anxiety and 7 for depression) which people rate on a four-point Likert scale (0-21 for both). Higher scoring indicates more symptoms, ≥ 11 points anxiety or depression is probable, ≥ 8-10 possible cases, \< 7 no cases. The HADS is highly reliable and valid and is an extensively used scale in internal medicine research \[[@B29],[@B30]\].

4\) The Fatigue-Numerical-Scale (FNS), an instrument measuring fatigue between 0 (no fatigue) and 10 (worst fatigue); ≥ 4 stands for moderate, ≥ 7 for severe fatigue \[[@B31],[@B32]\].

5\) Single items regarding thermoregulation (ie. congestive perspiration or freezing) \[[@B23]\]

6\) The Karnofsky Performance Index (KPI) which is a physician-assessed, general robust indicator of physical functioning in daily life \[[@B33]\].

Additionally for convergent validity, we documented the last haemoglobin level in the blood (g/dl) before inclusion of all patients with malignancies.

Results of the simultaneous validation of the German version of the Cancer Fatigue Scale (CFS-D) \[[@B34]\] and of the Internal Coherence Scale (ICS) \[[@B35]\] have been published elsewhere.

Study 2: State-aR responsiveness to chemotherapy treatment
----------------------------------------------------------

From April 2003 to March 2007, the Centre for Tumour Therapy at the Gemeinschaftskrankenhaus Havelhöhe, the Oncological Practices in Oschelbronn and Havelhöhe carried out the second study to test responsiveness of the State-aR questionnaire in the context of chemotherapy treatment. After explanation of the procedure and obtaining informed consent, we recruited consecutive breast cancer (B) and colorectal cancer patients (C) with histologically proven tumours who received adjuvant or palliative chemotherapy and concomitant mistletoe therapy. The participants were between 18 and 85 years old with a KPI \> 70% at baseline The oncologically scheduled chemotherapy, radiotherapy or mistletoe therapy was not impacted or changed by the study so that this second part of the validation study only measured the changing sensitivity (responsiveness) of the instruments. Therefore, study 2 is not a pharmacological study to test effectiveness of the treatment which was administered as a routine procedure in the study centres, but a validation and sensitivity testing of the instruments.

The State-aR responsiveness was compared to the Trait-aR version before, during and after adjuvant or palliative chemotherapy.

1\) Breast cancer patients who received adjuvant complementary treatment with standardized whole plant extracts of Viscum album L. (mistletoe) as standard therapy from the first cycle of chemotherapy (B) or

2\) Colorectal cancer (CRC) group (C) was also surveyed prior to the first cycle of chemotherapy with adjuvant mistletoe therapy.

For this purpose, the surveys were carried out 1 - 5 days prior to the start of chemotherapy (B, C), 1 - 5 days after the third cycle as well as 4 - 8 weeks after the end of chemotherapy using the State-aR and Trait-aR, and EORTC QLQ-C30 HRQL measure \[[@B2]\]. For KPI, stage of cancer, surgery and chemotherapy see Table [2](#T2){ref-type="table"}.

Statistical analysis of both studies
------------------------------------

The primary outcome of the validation study was to develop a reliable, valid and sensitive questionnaire on autonomic regulation for cancer patients.

For this purpose we conducted a listwise first reliability analysis for all 23 items along the following criteria:

1\) The Item-Total-Correlations being ≥ 0.10 and ≥ 0.70

2\) The α -if item deleted-analysis of every item should not achieve higher values than the Cronbach-α of every item.

3\) The remaining items were examined as to sufficient item population.

4\) Following that a reliability analysis (item-item-, item-total-, Cronbach-α - and test-retest-reliability) is carried out. Due to the concept-based heterogeneity of the items for different autonomic functions the following limits were determined for the sum-scale: Cronbach-α and test-retest-reliability: \> 0.70.

5\) The test-retest reliability was assessed with Spearman\'s rank correlation. The test-retest-reliability should be below that of the trait-scale.

6\) On the basis of these pre-selected items for all participants a principal component analysis (rotation: Varimax with Kaiser normalization) was conducted with optimality assessment of the two-, three- four-and five-factor model respectively, at a minimum factor load of r = 0.40.

7\) The Trait-aR questionnaire was used as a main convergence criterion. In addition, we performed a Spearman\'s rank correlation analysis for the whole sample, testing for associations between the State-aR sum- and subscales on the one hand and the assumed convergence criteria on the other. Correlation coefficients were determined with Spearman\'s rank correlations between Trait- and State-aR.

8\) We assessed the discriminant validity by applying the exact Mann-Whitney U-test to check whether State-aR sum- and subscales and Trait-aR are differentiating between cancer and healthy controls, and by comparing both results.

9\) We estimated the responsiveness in measuring chemotherapy sensitivity within the B and C group with the one-sided Wilcoxon-rank test between first and second and second and third test-point.

10\) We tested for superior sensitivity in state-aR over trait-aR by comparing standardized versions of both scales with Wilcoxon signed-rank test.

All analyses were performed with SPSS 16.0 software.

Results study 1
===============

Participants
------------

We invited 59 patients with malignant conditions and 59 healthy controls to participate. In total, 114 agreed to participate (97% recruitment). From the 57 recruited cancer patients there were 41 women and 16 men with a mean age of 59.3 years. Age and gender matching with the comparison group was successful (Table [1](#T1){ref-type="table"}). Twenty-two patients had no metastases, 35 had a metastatic or generalized disease. The median KPI at the time of recruitment was 90%. The duration of the malignancy was an average of 2.9 years. The mean haemoglobin (Hb) level was 12.1 g/dl (SD = 1.84). The questionnaire was re-administered to 65 participants (57.3%). Further participant details are listed in Table [2](#T2){ref-type="table"} and a summary of diagnoses in Table [3](#T3){ref-type="table"}.

Pretest on reliability
----------------------

Because of insufficient item-total correlation and α-if item deleted-analysis five items were eliminated from the scale: \'remembering dreams\', \'vivid dreams\', \'being able to digest big meals\', \'feeling well\' and \'stool consistency\'. This left 18 items in the scale (Table [4](#T4){ref-type="table"}).

Field completion
----------------

Apart from the following four items and missing answers, all other fields were completed:

\'Feeling dizzy when turning round\' (missing answer 1 (a lot)), \'feeling dizzy when getting up in the morning\' (a lot), \'feeling dizzy when bending down or getting up\' (a lot) and \'cold and sweaty extremities\' (a lot). Therefore the answer frequency varies from 0% to 70.2% in each case for answers 5 of the questions \'feeling dizzy when turning round quickly\' and \'cold and sweaty hands\' (Table [4](#T4){ref-type="table"}). The mean values vary from 3.22 (stool frequency) to 4.58 (\'feeling dizzy when turning round quickly\').

Principal component analysis
----------------------------

Primary factor analysis pointed to a three-principal-component model as we achieved for the Trait-aR scale \[[@B22]\]. This model showed an unambiguous, clear factor loading pattern. However, factor one - consisting of the rest/activity and orthostatic-circulatory items - was overwhelmingly dominant compared to the thermo-sweating and digestive factors (12, 3 and 3 items). Yet, although slightly more complex, a four-principal components model proved superior with regard to factual and content criteria (comparative factor pattern to the trait scale). Principal component 1 (rest/activity regulation) was analysed by 8 items (range: 8-40) and explained 17.8% of variance; the second principal component (orthostatic-circulatory regulation) was analysed by 4 items (4-20) which explained 14.5% of variance; the third component (thermo-sweating regulation) was analysed by 3 items and explained 12.8% of variance; the fourth component (digestive regulation) was also analysed by 3 items (3-15) and explained 10.8% of the variance (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). In this model, all factors had a minimum eigenvalue close to 2 in the Kaiser criteria and show a largely unambiguous item analysis pattern for the four components. Compared to this the alternatively tested five-principal-components model resulted in a series of ambiguous loading patterns. Therefore the four-principal-components model selected was the only convincing model.

Analysis of reliability
-----------------------

The principal results of the reliability analysis were the following:

Item-item-correlations: mean of the correlations is r = 0.22, min/max = -0.18/0.73, range = 0.91. The item-variance has a mean of 1.08 (min/max = 0.56/1.86, range = 1.29). The item-total-correlation is r~tr~= 0.12 (bowel movements frequency) - 0.56 (disturbed sleep). The internal consistency measured with Cronbach-α is r~α~= 0.83, the test-retest-reliability: r~rt~= 0.79 (p \< 0.001) (Table [5](#T5){ref-type="table"}). The reliability analysis of the subscales show Cronbach-α between r~α~= 0.85 (thermo-sweating regulation) and r~α~= 0.70 (digestive regulation). Factor 3 (thermo-sweating regulation) has the lowest test-retest-reliability with r~rt~= 0.60, the highest was measured for factor 1 (rest/activity regulation, r~rt~= 0.79) (Table [5](#T5){ref-type="table"}). The subscales correlated with one another (0.47-0.28) with the exception of the digestive regulation subscale (r = 0.12-0.02) (Table [6](#T6){ref-type="table"}).

###### 

Overview over the items of the State aR with their distribution over the different subscales: Arranged from top to bottom for State rest/activity, State orthostatic-circulatory, State digestive and State thermo-sweating regulation with details on mean (SD), minima/maxima and concurrent validity for item/total and item/subscale correlation with Trait aR sum scale.

  Items                                                                     Mean (SD)          Min/Max     **Item-Trait aR18 correl**.   Item-Subscale State-aR   Item-total-correlation   Factor Loading   α-if item deleted total scale   **Cronbach- α/Test-retest Rel**.
  ------------------------------------------------------------------------- ------------------ ----------- ----------------------------- ------------------------ ------------------------ ---------------- ------------------------------- ----------------------------------
  I had cold hands or feet                                                  3.81 (1.16)        1-5         **0.24**                      **0.45**                 **0.35**                 **0.556**        **0.816**                       
  I was able to fall asleep                                                 3.87 (0.96)        1-5         **0.49**                      **0.50**                 **0.46**                 **0.607**        **0.809**                       
  I had to pull myself together to do things                                3.39 (1.13)        1-5         **0.36**                      **0.51**                 **0.48**                 **0.676**        **0.808**                       
  I felt rested in the morning                                                                                                                                                                                                              
  I suffered from stomach rumbling                                          3.89 (1.11)        1-5         **0.39**                      **0.47**                 **0.45**                 **0.528**        **0.810**                       
  There were situations where I felt less competent or skilful than usual   3.80 (1.15)        1-5         **0.39**                      **0.61**                 **0.49**                 **0.749**        **0.807**                       
  My sleep was restless                                                     3.58 (1.12)        1-5         **0.39**                      **0.53**                 **0.56**                 **0.540**        **0.803**                       
  I had cold and sweaty hands or feet                                       4.54 (0.79)        2-5         **0.34**                      **0.43**                 **0.42**                 **0.507**        **0.812**                       
                                                                                                                                                                                                                                            
  **S Rest/activity regulation**                                                                                                                                                                                                            
  I felt dizzy when turning round                                           4.54 (0.75)        2-5         **0.46**                      **0.61**                 **0.52**                 **0.770**        **0.809**                       **0.805/0.792**
  I felt dizzy when getting up in the morning                               4.58 (0.75)        2-5         **0.32**                      **0.60**                 **0.49**                 **0.734**        **0.810**                       
  I felt dizzy when turning round quickly                                   4.07 (1.07)        1-5         **0.36**                      **0.59**                 **0.40**                 **0.743**        **0.813**                       
  I felt dizzy when getting up or bending down                              4.23 (0.82         2-5         **0.43**                      **0.66**                 **0.48**                 **0.791**        **0.810**                       
                                                                                                                                                                                                                                            
  **S Orthostatic-circulatory regulation**                                  **17.41 (2.70)**   **9-20**    **0.48**                      **0.60**                 **0.68**                                                                  **0.804/0.650**
  I suffered from night sweats                                              3.84 (1.25)        1-5         **0.50**                      **0.66**                 **0.46**                 **0.784**        **0.810**                       
  I sweated                                                                 3.46 (1.07)        1-5         **0.40**                      **0,82**                 **0.37**                 **0.915**        **0.815**                       
  I sweated even during light physical activity                             3.75 (1.10)        1-5         **0.39**                      **0.67**                 **0.38**                 **0.836**        **0.814**                       
                                                                                                                                                                                                                                            
  **S Thermo-sweating regulation**                                          **11.06 (3.00)**   **3-15**    **0.49**                      **0.48**                 **0.58**                                                                  **0,852/0.601**
  I had bowel movements                                                     3.22 (0.95)        1-5         **0.22**                      **0.45**                 0.12                     **0.806**        **0.827**                       
  I had bowel movements - as always - at certain times of the day           3.25 (1.37)        1-5         **0.24**                      **0.41**                 0.16                     **0.853**        **0.829**                       
  I suffered from constipation                                              4.42 (1.04)        1-5         **0.32**                      **0.65**                 **0.38**                 **0.615**        **0.814**                       
                                                                                                                                                                                                                                            
  **S Digestive regulation**                                                **10.89 (2.65)**   **3-14**    **0.29**                      **0.69**                 **0.44**                                                                  **0.696/0.767**
                                                                                                                                                                                                                                            
  **S aR Total Scale**                                                      **69.75 (9.25)**   **44-89**   **0.76**                                                                                                                         **0.832/0.795**
                                                                                                                                                                                                                                            
  **T aR Total Scale**                                                      **42.42 (5.26)**   **26-54**                                                                                                                                    **0.741 0.867**
                                                                                                                                                                                                                                            
  **T aR Orthostatic-circulatory**                                          **16.49 (6.78)**   **10-21**   **0.69**                                                                                                                         **0.676 0.803**
                                                                                                                                                                                                                                            
  **T aR Rest/activity**                                                    **18.72 (10.9)**   **11-24**   **0.77**                                                                                                                         **0.697 0.833**
                                                                                                                                                                                                                                            
  **T aR Digestive**                                                        **7.26 (1.52)**    **3-9**     **0.49**                                                                                                                         **0.623 0.879**

Furthermore, item-total-correlation, factor loading, α-if item deleted for the subscales, Cronbach-α and retest reliability are presented (significant correlation, p \< 0.05 shown in bold).

###### 

Correlation matrix of the State-aR sum- and subscales and the Trait-aR sum- and subscales with one another and Karnofsky-Index (KPI), A-HADS\* & D-HADS\* (\*high values more symptoms), Self-regulation scale (SRS), haemoglobin, questions on thermoregulation, EORTC functions and role scales, EORTC Symptoms Scales\* (\*high values more symptoms) (significant correlation, p \< 0.05 shown in bold).

                                              S-aR Total scale   S-Rest/activity Ar   S-Orthostatic-circulatory aR   S-Thermo-sweating aR   S-Digestive aR   T-aR Total scale   T-Rest/activity aR   T-Orthostatic-circulatory aR   T-Digestive aR
  ------------------------------------------- ------------------ -------------------- ------------------------------ ---------------------- ---------------- ------------------ -------------------- ------------------------------ ----------------
  **Study 1: S-Rest/activity aR**             **0.85**                                                                                                                                                                              
  **Study 1: S-Orthostatic-circulatory aR**   **0.65**           **0.47**                                                                                                                                                           
  **Study 1: S-Thermo-sweating aR**           **0.55**           **0.25**             **0.28**                                                                                                                                      
  **Study 1: S-Digestive aR**                 **0.36**           0.12                 0.02                           0.09                                                                                                           
  **Study 1: T-aR**                           **0.74**           **0.58**             **0.48**                       **0.48**               **0.29**                                                                                
  **Study 1: T-Rest/activity**                **0.62**           **0.58**             **0.26**                       **0.48**               0.10             **0.92**                                                               
  **Study 1: T-Orthostatic-circulatory aR**   **0.52**           **0.40**             **0.60**                       **0.31**               0.02             **0.53**           0.28                                                
  **Study 1: T-Digestive aR**                 **0.33**           0.16                 0.08                           0.03                   **0.69**         0.23               0.07                 0.27                           
  **Study 1: KPI**                            **0.59**           **0.66**             **0.28**                       0.17                   0.09             **0.42**           **0.39**             **0.28**                       0.14
  **Study 1: A-HADS\***                       **-0.44**          **-0.41**            **-0.33**                      **-0.31**              **-0.31**        **-0.55**          **-0.53**            **-0.43**                      -0.15
  **Study 1: D-HADS\***                       **-0.43**          **-0.48**            **-0.48**                      **-0.22**              **-0.22**        **-0.43**          **-0.47**            **-0.29**                      **-0.22**
  **Study 1: SRS**                            **0.41**           **0.37**             **0.24**                       **0.25**               **0.25**         **0.32**           **0.22**             **0.23**                       0.17
  **Study 1: FNS\***                          **-0.44**          **-0.50**            **-0.29**                      -0.13                  -0.01            **-0.40**          **-0.40**            **-0.22**                      -0.06
  **Study 1: Haemoglobin**                    0.26               **0.31**             0.07                           -0.10                  0.13             0.29               0.27                 0.15                           0.25
  **Study 1: Congestive perspiration**        **0.41**           **0.29**             **0.26**                       **0.43**               0.05             **0.31**           **0.39**             0.19                           -0.03
  **Study 1: freezing**                       **0.40**           **0.45**             **0.19**                       **0.22**               0.01             **0.44**           **0.39**             **0.41**                       0.06
  **Study 2: EORTC Physical funct**.          **0.40**           **0.49**             0.14                           0.25                   0.02             **0.34**           **0.36**             0.20                           -0.21
  **Study 2: EORTC Role funct**.              0.27               0.23                 0.10                           0.21                   0.17             0.22               0.21                 0.08                           -0.07
  **Study2: EORTC Emotional funct**.          **0.69**           **0.71**             0.23                           **0.39**               0.02             **0.52**           **0.48**             **0.44**                       -0.10
  **Study 2: EORTC Cognitive funct**.         **0.48**           **0.58**             0.26                           0.04                   0.01             **0.39**           0.28                 **0.56**                       -0.18
  **Study 2: EORTC Social funct**             0.25               **0.31**             -0.20                          0.06                   0.20             0.29               0.27                 0.21                           -0.10
  **Study 2: EORTC Global Health**            **0.52**           **0.50**             0.14                           0.19                   0.30             **0.43**           **0.39**             0.21                           0,09
  **Study 2: EORTC Fatigue\***                **-0.35**          **-0.35**            -0.20                          -0.08                  -0.04            -0.24              -0.18                -0.21                          0.07
  **Study 2: EORTC Dyspnea\***                **-0.46**          **-0.36**            **-0.50**                      -0.20                  -0.11            **-0.34**          -0.22                **-0.54**                      0.07
  **Study2: EORTC Sleep**                     **-0.60**          **-0.56**            -0.23                          -0.30                  -0.00            **-0.43**          **-0.45**            -0.10                          -0.14

Construct validity
------------------

All 18 items correlated positively with the Trait-aR scale, ranging from r = 0.50 (sweat at night) to r = 0.22 (p \< 0.05) (bowel movement frequency) (Table [5](#T5){ref-type="table"}). The test-retest results of the State-aR with r = 0.60 (S-thermo-sweating regulation) to r = 0.79 (S-rest/activity regulation) are lower compared to those of the Trait-aR (Trait-aR r = 0.80 (T-orthostatic-circulatory aR) - r = 0.88 (T-digestive aR) (all p \< 0.001).

The concurrent validity of the State and the Trait-scales ranged from r = 0.48 to 0.74 (Tables [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}). The following convergence criteria showed positive correlations to high State-aR inclusive of all subscales: low anxiety (r = -0.44-0.31), low depression (r = -0.48 - -0.22), high self-regulation (r = 0.41-0.24). The following correlated with the sum-scale and the first three subscales: less congestive sweating (r = 0.43 - 0.26) and less \'feeling cold\' (r = 0.45-0.19) and to the first two subscales and the sum scale: high KPI (r = 0.66-0.28), lower FNS (r = 0.50-0.29). Rest/activity regulation correlated with higher haemoglobin (r = 0.31) and more frequent fevers when suffering from colds (r = 0.20).

The sum-scale values distributed from 44 to 89 with a mean value of 69.6; the theoretical minimum/maximum-limits are 18-90. The determination of the discrimination validity was achieved via comparison between the healthy control group and the cancer patients with regards to separation properties between the State-aR-scales compared to the Trait-aR scale (exact U-Test Mann-Whitney: State-aR: z = 4.4, p \< 0.001; Trait-aR: z = 1.70, p = 0.090, S-rest/activity aR: z = 5.0 (p \< 0.001), T-rest/activity aR: z = 2.70 (p = 0.006); S-orthostatic-circulatory aR: z = 1.3 (p = 0.21), T-orthostatic-circulatory: z = 0.31 (p = 0.75); S-thermo-sweating aR: z = 1.5 (p = 0.14); S-digestive aR: z = 2.43 (p = 0.015), T-digestive: z = 2.18 (p = 0.029); therefore the State-aR compared to the Trait-aR shows higher separation properties (Table [7](#T7){ref-type="table"}).

###### 

Means and SD for all patients and controls and separated into women and men for the State aR total scale and subscales (State rest/activity, State orthostatic-circulatory, State thermosweating and State digestive regulation) and Trait aR total and subscales (Trait rest/activity regulation, Trait orthostatic-circulatory, Trait digestive regulation).

                          S-aR Total scale   S-Rest-activitiy aR   S-Orthostatic-circulatory aR   S-Thermo-sweating aR   S-Digestive aR   T-aR Total scale   T-Rest-activity aR   T-Orthostatic-circulatory aR   T-Digestive aR
  ----------------------- ------------------ --------------------- ------------------------------ ---------------------- ---------------- ------------------ -------------------- ------------------------------ ----------------
  **Study 1**                                                                                                                                                                                                    
                                                                                                                                                                                                                 
  **Patients**                                                                                                                                                                                                   
  Mean all                **65.86**          **27.81**             17.12                          10.61                  **10.30**        **41.49**          **17.85**            **1**6.57                      **7.00**
  (SD)                    **(9.20)**         **(5.11)**            (2.83)                         (3.21)                 **(2.86)**       (5.70)             **(3.51)**           (2.72)                         **(1.53)**
  Mean women              **65.24**          **27.51**             17.00                          10.07                  **10.63**        40.54              **17.59**            16.00                          **6.95**
  (SD)                    **(8-77)**         **(4.94)**            (2.97)                         (2.95)                 **(2.97)**       (5.54)             **(3.37)**           (2.67)                         **(1.49)**
  Mean men                67.44              **28.56**             17.44                          10.56                  10.87            44\. 14            **18.53**            18.07                          **7.12**
  (SD)                    (10.36)            **(5.64)**            (2.68)                         (3.86)                 (2.63)           (5.48)             (3.87)               (2.34)                         (1.67)
                                                                                                                                                                                                                 
  **Control**             **73.65**          **32.96**             17.70                          11.51                  **11.47**        43.36              **19.55**            16.41                          **7.51**
  Mean all (SD)           **(7.56)**         **(4.31)**            (2.54)                         (2.73)                 **(2.31)**       (4.65)             **(2.87)**           (2.50)                         **(1.48)**
  Mean women              **73.27**          **32.39**             17.78                          11.37                  **11.73**        42.45              **18.90**            16.03                          **7.59**
  (SD)                    **(7.49)**         **(4.55)**            (2.66)                         (2.84)                 **(1.98)**       (4.63)             **(2.99)**           (2.50)                         **(1.32)**
  Mean men                74.62              **34.44**             17.50                          10.81                  11.87            42.45              18.90                16.03                          7.59
  (SD)                    (7.89)             **(3.31)**            (2.28)                         (2.97)                 (2.47)           (4.63)             (2.99)               (2.50)                         (1.32)
                                                                                                                                                                                                                 
  p-value                 **\< 0.001**       **\< 0.001**          0.21                           0.14                   **0.015**        0.090              **0.006**            0.75                           **0.029**
                                                                                                                                                                                                                 
  Patients vs Control\*                                                                                                                                                                                          
                                                                                                                                                                                                                 
  **Study 2**                                                                                                                                                                                                    
                                                                                                                                                                                                                 
  Breast cancer           **70.29**          **30.76**             17.18                          10.65                  11.65            41.53              17.56                16.62                          7.35
  group 1 T0              **(6.72)**         **(3.47)**            (2.43)                         (2.42)                 (1.73)           (4.41)             (3.31)               (1.59)                         (1.06)
  Breast cancer           **67.50**          **28.94**             17.19                          10.81                  10.50            40.25              17.50                16.06                          6.76
  group 1 T1              **(10.59)**        **(6.16)**            (3.51)                         (2.74)                 (2.66)           (6.54)             (3.60)               (3.11)                         (1.60)
  Breast cancer           67.65              29.75                 16.65                          10.53                  10.94            41.12              17.41                16.47                          7.23
  group 1 T2              (10.09)            (5.93)                (3.82)                         (3.20)                 (2.68)           (6.53)             (3.69)               (2.87)                         (1.39)
  Colorectal cancer       **73.39**          **31.27**             18.38                          12.44                  11.09            43.83              19.08                17.25                          7.38
  T0                      **(8.62)**         **(5.24)**            (2.28)                         (2.48)                 (2.88)           (4.13)             (2.86)               (1.77)                         (1.64)
  Colorectal cancer       **69.87**          **28.46**             17.46                          12.42                  11.58            43.29              18.81                17.04                          7.57
  T1                      **(12.11)**        **(6.78)**            (3.39)                         (3.30)                 (2.19)           (5.22)             (3.47)               (2.16)                         (1.34)
  Colorectal cancer       71.25              30.20                 16.91                          12.36                  11.74            43.67              18.95                17.04                          7.71
  T2                      (10.04)            (5.99)                (3.45)                         (1.91)                 (1.42)           (5.13)             (3.42)               (2.07)                         (1.00)
  p-value T0 vs T1 \*\*   **0.010**          **0.001**             0.243                          0.413                  0.325            *0.079*            0.226                *0.061*                        0.306
  p-value T1 vs T2\*\*    0.484              *0.061*               0.106                          0.395                  0.114            0.243              0.432                0.222                          0.119

Significant results are shown in bold.

\*Exact U-Test (2-side) between Cancer group and healthy controls,

\*\* Exact Wilcoxon-Test (1-side) used for pooled breast cancer and colorectal cancer and tests T0 (before chemotherapy) vs. T1 (1-5 days after third chemotherapy cycle) and T1 vs, T2 (4-8 weeks after the end of chemotherapy).

Significant differences (p \< 0.05) are shown in bold.

Results study 2
===============

21 patients with breast cancer consented to the study, three declined further participation after their first chemotherapy session, leaving 18 patients who completed the first re-test questionnaire, and one declining the third questionnaire. Therefore we had three completed questionnaires from 17 patients (81%). 29 patients with colorectal cancer were initially consented to the study, one did not receive chemotherapy, and another declined further participation after their first chemotherapy, session 27 patients completed three questionnaires, before, during and after chemotherapy respectively. 25 (86%) of these could be fully evaluated at all three stages.

State-aR total-scale and rest/activity correlated to varying degrees to HRQL as assessed with the EORTC (r = 0.70 - 0.23) and symptom scales (r = -0.60 - -0.07). Orthostatic-circulatory, thermo-sweating and digestive show just single correlations to the HRQL and symptom scales (r = -0.56 - 0.00). Of outstanding relevance is the moderate to strong correlation between the sum- and rest/activity scale and the EORTC\'s \"Emotional Functioning\" and sleep disturbances (r = 0.71 - 0.56) (Table [6](#T6){ref-type="table"}).

The pooled breast cancer group and CRC group showed a significant reduction of the State-aR sum-and rest/activity scales during chemotherapy while the other State-aR subscales and the Trait-aR scale and subscales show no significant difference (Table [7](#T7){ref-type="table"}). We compared the sensitivity of both state and trait-aR questionnaires during and outside of chemotherapy treatment. We detected a non-significant increase in sensitivity for the state-aR.

Discussion
==========

The newly developed scale measuring autonomic regulation as a state (State-aR) relating to the previous week shows good -its subscales a satisfactory to good-internal consistency \[[@B36]\], which is continuously higher than that of the Trait-Version. The median four week test-retest reliability of the State-aR is 0.05-0.15 lower than of the Trait-Version, which is coherent with the distinction between state and trait characteristics. The five-week test-retest reliability of the Trait sum-scale, rest/activity and orthostatic-circulatory measured in this study is only marginally higher (0.02\--0.15) than that of the three-month test-retest reliability of the published Trait-Version \[[@B23],[@B22]\], which points towards temporal stability of the Trait questionnaire \[[@B37]\].

The State-aR shows a strong correlation with the Trait-aR concurrent test with an r = 0.74 and the three parallel subscales (0.58-0.69), consistent with so that a largely comparable construct, although relating to different time frames (previous week/in general). For patients undergoing chemotherapy, the State-aR scale recorded a significant loss of regulation in the sum-and rest-activity subscales, compared to the Trait-aR scale. Cross-sectional studies have repeatedly shown a lowered Trait-aR for breast cancer patients vs. healthy individuals \[[@B22],[@B25],[@B23]\]. Hence the State-aR captures an increase in sleep problems and problems in daily functioning which is related to fatigue during chemo-or radiotherapy \[[@B14],[@B38]-[@B40]\]. A robust assessment of stability and responsiveness of the Trait-State-aR scale requires further data for validation in patients with other chronic conditions. Compared to other state and trait evaluations such, as for instance, the State and Trait Anxiety Inventory (STAI) the test-retest reliability of the State-aR is higher as its questions relate to the preceding week whereas the State-STAI queries the immediate current state (such as for instance stress experienced at the start of an exam) \[[@B41],[@B37]\]. HRQL and self-assessment questionnaires should be clinically relevant and therefore also record a clinically relevant time frame. There is some controversy as to how long this time frame should be \[[@B42],[@B43]\], but the most commonly used time frames range is from one week to four weeks \[[@B3],[@B44]\].

In order to ensure that the questionnaire construct on State-aR was sufficiently broad we had to accept items with a heterogeneity which capture the different autonomic functions and which had already been validated in the Trait version on aR \[[@B22]\]. This explains one limitation of this validation, that the low item-total correlation for \'bowel movements\'(r = 0.12) with a low concurrent correlation to the Trait scale of r = 0.22 \[[@B45]\]. Further limitations are that items such as \'travel sickness\', \'dizziness from circular motions\' could not be sensibly transformed into a State version relating to the previous week \[[@B22]\]. This is why not all State questions can be matched to identical Trait items. The State-aR scale also differs from the Trait-aR scale with regards to the factor solution as the thermosweating scale is added as the fourth scale \[[@B22]\] which is explained through the additional item \'activity-dependent sweating\'.

The four factor solution however still fulfils all common criteria of the test theory with item-subscale-correlations r \> 0.40, with clear factor loading, good factor differentiation as regards to content as well as satisfactory to good internal consistency \[[@B45]\]. The individual Trait question \'cold and cold and sweaty hands\' is split into \'cold hands\' and \'cold and sweaty hands\' and the sum scale is also supplemented by two items (\'fine motor skills\', \'activity-dependent sweating\'). This, next to a new thermo-sweating subscale, lead to a different weight- and loading pattern: the rest/activity regulation contains more items, including the questions on \'fine motor skills\' and the two questions relating to \'cold extremities\" which, other than in the Trait scale, are no longer included under the section on orthostatic-circulatory regulation \[[@B22]\]. One methodological limitation is that we have calculated test-retest reliability based only on 57% of all participants in study 1.

Similar to the STAI, where the State-anxiety is described as situational anxiety and Trait-anxiety described as individual, relatively stable anxiety with high test-retest reliability \[[@B41]\], the State-aR can detect a loss of regulation due to illness or also through stressors. The Trait-aR on the other hand can be conceived as a combination of autonomic constitution and current regulation \[[@B22]\]. The new State-aR sum-scale as Opposed to the Trait-scale in a cross-sectional context shows a significantly lower aR of the cancer group compared to the control group. In contrast, the State-as well as the Trait subscales on rest/activity and digestive regulation distinguish between cancer patients and the healthy control group, with the State-scale separating them more clearly. Even, if the sensitivity analysis between both questionnaires yielded to no significant difference between both scales.

The aR-values determined via self-assessment capture autonomic lability (low aR) on the one hand and autonomic stability (high aR) on the other in the sense of an autonomic functioning of the three function scales and the rest/activity scale. High aR correlates low- moderately with the experience of comfort and good thermoregulation (regulated between feeling cold/peripheral vasoconstriction and sweating during heat) \[[@B23],[@B22]\]. These results support data describing a strong regulated thermo-regulatory threshold level between perspiration and vasoconstriction, which is dependent not only on circadian rhythm but also on vigilance, personality and gender \[[@B46]\].

The strong correlation of aR and rest/activity to the KPI is a measure of its convergence validity. The rest/activity regulation and the circadian change of performance orientation during the day (ergotropy) and autonomic order during night sleep (vagotonia) were already recognised to be relevant to health status in the 1960s \[[@B47]\]. We have shown positive correlations of aR to health and illness for 18 to 93-year-olds in cross-sectional studies \[[@B22],[@B24]\]. The low correlation to haemoglobin and moderate correlation to lower anxiety and depression for the State-scale was comparable to the Trait subscales \[[@B24]\]. High aR appears to go hand in hand with fewer distress symptoms \[[@B48]\].

The self- regulation scale \[[@B27]\] consists of two subscales entitled \'achieve satisfaction and well-being\' and \'change behaviour to reach goal\' \[[@B28]\]. The moderate relationship of aR with self-regulation may indicate both autonomic and psychosomatic interactions. In the case of self-regulation, this is a consistent independent prognostic factor for cancer patients \[[@B27],[@B49],[@B50]\]. Whilst it was not possible to demonstrate an impact of aR on the survival for breast cancer and colorectal cancer patients in contrast to self-regulation \[[@B50]\], aR is a prognostic factor for CRF and cognitive fatigue \[[@B51]\]. The question as to whether aR correlates with the actigraphical measured rest/activity and if it could be a prognostic factor for other chronic conditions awaits the results of ongoing studies.

Our findings suggest that the new questionnaire on State-aR could be more sensitive in detecting the loss of aR in cancer patients than the Trait-scale. Further research is need to clarify over what period of time the state-aR is more sensitive than the trait-aR scale and to what extent it sensitively measures successful therapy, side effects or progress of malignant conditions. The new scale on State-aR is an instrument which in future can be used to assess adjuvant, palliative and rehabilitative treatments. We are particularly interested in its use in the context of complex oncological, palliative medicine and the effectiveness of complementary medical treatments concepts such as mistletoe or non-pharmacological therapies such as exercise, eurythmy or art-therapy \[[@B52],[@B53]\].
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